Genes, BRCA2
-
Subject Areas on Research
- A recessive variant of XRCC4 predisposes to non- BRCA1/2 breast cancer in chinese women and impairs the DNA damage response via dysregulated nuclear localization.
- Abdominal Imaging of Pancreatic Cysts and Cyst-Associated Pancreatic Cancer in BRCA1/2 Mutation Carriers: A Retrospective Cross-Sectional Study.
- Adherence to Recommended Risk Management among Unaffected Women with a BRCA Mutation.
- An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions.
- Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.
- BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma.
- BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.
- Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers.
- Cancer yield of mammography, MR, and US in high-risk women: prospective multi-institution breast cancer screening study.
- Changes in diet and physical activity following BRCA1/2 testing.
- Characterization of BRCA1 and BRCA2 mutations in a large United States sample.
- Clinical and Genetic Risk Prediction of Subsequent CNS Tumors in Survivors of Childhood Cancer: A Report From the COG ALTE03N1 Study.
- Comparing Mammography Abnormality Features to Genetic Variants in the Prediction of Breast Cancer in Women Recommended for Breast Biopsy.
- Coping with genetic testing for breast cancer susceptibility.
- DNA patents and diagnostics: not a pretty picture.
- Ductal carcinoma in situ in BRCA mutation carriers.
- Evaluation and optimisation of indel detection workflows for ion torrent sequencing of the BRCA1 and BRCA2 genes.
- Feasibility of breast duct lavage performed by a physician extender.
- Genetic testing in ovarian cancer: getting better, and maybe not just for disease susceptibility anymore.
- Genetic variants in fanconi anemia pathway genes BRCA2 and FANCA predict melanoma survival.
- Genetics and women's health issues--the commitment of EMS to women scientists and gender-associated disease topics.
- Genomic tests for ovarian cancer detection and management.
- Increased in vitro and in vivo sensitivity of BRCA2-associated pancreatic cancer to the poly(ADP-ribose) polymerase-1/2 inhibitor BMN 673.
- Individualized survival curves improve satisfaction with cancer risk management decisions in women with BRCA1/2 mutations.
- Interest in BRCA1/2 testing in a primary care population.
- Limited family structure and breast cancer risk.
- Male breast cancer during treatment with leuprolide for prostate cancer.
- Molecular evolution of a Drosophila homolog of human BRCA2.
- Molecular testing for the BRCA1 and BRCA2 Ashkenazi Jewish founder mutations: a report on the College of American Pathologists proficiency testing surveys.
- Moving Beyond "Isolated" Gene Patents
- Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer.
- Pre-counseling education materials for BRCA testing: does tailoring make a difference?
- Prophylactic and risk-reducing bilateral salpingo-oophorectomy: recommendations based on risk of ovarian cancer.
- Psychological distress and quality of life associated with genetic testing for breast cancer risk.
- Randomized trial of a decision aid for BRCA1/BRCA2 mutation carriers: impact on measures of decision making and satisfaction.
- Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer.
- Role of genetic polymorphisms and ovarian cancer susceptibility.
- Slip-sliding away: serial changes and homoplasy in repeat number in the Drosophila yakuba homolog of human cancer susceptibility gene BRCA2.
- Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions.
- Targeted composite value-based endpoints in platinum-sensitive recurrent ovarian cancer.
- Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based Outreach.
- Validity of models for predicting BRCA1 and BRCA2 mutations.
- Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study.
-
Keywords of People
- Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology